IPAVNA Trademark

Trademark Overview


On Thursday, July 21, 2022, a trademark application was filed for IPAVNA with the United States Patent and Trademark Office. The USPTO has given the IPAVNA trademark a serial number of 97514050. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Friday, August 30, 2024. This trademark is owned by Clementia Pharmaceuticals Inc.. The IPAVNA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for use in the prevention and the treatment of cancer, orphan diseases, immune disorders, liver diseases, biliary diseases, metabolic diseases, inflammatory diseases, urological diseases, disorders and diseases of the reproductive system, puberty diseases or disorders, gynecological disorders, fertility, acromegalia and tumors, hormonal disorders, endocrine disorders, connective tissue diseases, blood diseases, gastrointestinal diseases and disorders, hemophilia, gastrointestinal bleeding disorders, neurological diseases, muscle disorders, bone disorders, skeletal disorders, neuromuscular disorders, cervical dystonia, cerebral palsy, spasticity, blepharospasm, migraine, bladder pain syndrome, pain, glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; pharmaceutical preparations containing botulinum toxin, botulinum toxin-haemagglutinin complex, botulinum toxin fragments and other botulinum toxin derivatives for skin car...
ipavna

General Information


Serial Number97514050
Word MarkIPAVNA
Filing DateThursday, July 21, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateFriday, August 30, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 26, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for use in the prevention and the treatment of cancer, orphan diseases, immune disorders, liver diseases, biliary diseases, metabolic diseases, inflammatory diseases, urological diseases, disorders and diseases of the reproductive system, puberty diseases or disorders, gynecological disorders, fertility, acromegalia and tumors, hormonal disorders, endocrine disorders, connective tissue diseases, blood diseases, gastrointestinal diseases and disorders, hemophilia, gastrointestinal bleeding disorders, neurological diseases, muscle disorders, bone disorders, skeletal disorders, neuromuscular disorders, cervical dystonia, cerebral palsy, spasticity, blepharospasm, migraine, bladder pain syndrome, pain, glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; pharmaceutical preparations containing botulinum toxin, botulinum toxin-haemagglutinin complex, botulinum toxin fragments and other botulinum toxin derivatives for skin care and the treatment of neurological disorders; pharmaceutical preparations containing botulinum toxin with specified component of the toxin haemagglutinin complex for skin care and the treatment of neurological disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 11, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameClementia Pharmaceuticals Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMontreal, Quebec H3B2V6
CA

Party NameClementia Pharmaceuticals Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMontreal, Quebec H3B4W5
CA

Trademark Events


Event DateEvent Description
Monday, July 25, 2022NEW APPLICATION ENTERED
Thursday, August 11, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, February 10, 2023ASSIGNED TO EXAMINER
Thursday, February 16, 2023PRIORITY ACTION WRITTEN
Thursday, February 16, 2023PRIORITY ACTION E-MAILED
Thursday, February 16, 2023NOTIFICATION OF PRIORITY ACTION E-MAILED
Tuesday, May 16, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Tuesday, May 16, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, August 14, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, August 15, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 14, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, August 22, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 6, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 26, 2023PUBLISHED FOR OPPOSITION
Tuesday, September 26, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 21, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 19, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, December 19, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, February 29, 2024SOU EXTENSION 1 GRANTED
Tuesday, December 19, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, February 29, 2024SOU TEAS EXTENSION RECEIVED
Thursday, February 29, 2024SOU EXTENSION 1 FILED
Friday, March 1, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 30, 2024SOU TEAS EXTENSION RECEIVED
Friday, August 30, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 30, 2024SOU EXTENSION 2 FILED
Friday, August 30, 2024SOU EXTENSION 2 GRANTED